Skip to main content
SpringerLink
Log in

Clinical evaluation of single or joint of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma diagnosing

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of the present study was to further evaluate the clinical value of single or joint of golgi protein 73 (GP73) and alphafetoprotein (AFP) in diagnosis of hepatocellular (HCC).

Methods

One hundred and eighteen, 94 and 47 serum samples from the patients with HCC, chronic liver disease (CLD) and liver cirrhosis (LC) were collected, respectively. Serum levels of AFP and GP73 were assayed with commercial kit according to the manufacturer’s instructions.

Results

Patients with HCC had higher serum concentration of AFP than that of the patients with CLD (P < 0.01), but was similar to that of the patients with LC. Serum GP73 levels in the patients with CLD or LC were significantly lower than that in the patients from HCC group (P < 0.01). Among 118 HCC patients, the positive rate of GP73 and AFP was 80.5% and 48.3%, respectively (P < 0.001). The ROC curve analysis showed that the AUC value of GP73 was higher than that of serum AFP. Moreover, the sensitivity and the accuracy of GP73 were 77.1% and 82.6%, respectively, which were greater more than that of AFP at 90% specificity (28.8% and 59.8%, respectively). The AUC, the sensitivity and the accuracy of GP73 in combination of AFP (AFP/GP73) were 0.855, 78.0% and 83.0%, respectively, which were similar to that of GP73 alone but were much higher than that of the single marker AFP.

Conclusion

For HCC diagnosing, GP73 was more sensitive and specific than AFP. The diagnostic value of AFP/GP73 was similar to GP73 but was much higher than AFP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wu MC. Clinical and experimental research of primary liver cancer in China. Chinese-German J Clin Oncol, 2002, 1: 1–4.

    Article  Google Scholar 

  2. Yang SL, Pan XL, Xiong ZF, et al. The influence of hepatitis B virus X protein on the clock genes in liver cells and its significance. Chinese-German J Clin Oncol, 2011, 10: 468–471.

    Article  CAS  Google Scholar 

  3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379: 1245–1455.

    Article  PubMed  Google Scholar 

  4. Ochiai T, Ikoma H, Murayama Y, et al. Factors resulting in 5-year disease-free survival after resection of hepatocellular carcinoma. Anticancer Res, 2012, 32: 1417–1422.

    PubMed  Google Scholar 

  5. Chen XM, Luo PF, Lin HH, et al. Protocol of interventional treatment for hepatocellular carcinoma. Chinese-German J Clin Oncol, 2005, 4: 112–115

    Article  Google Scholar 

  6. Yamashita T, Kaneko S. Treatment strategies for hepatocellular carcinoma in Japan. Hepatol Res, 2012 April 13.

  7. Kudo M. Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology, 2011, 81: 73–85.

    Article  PubMed  CAS  Google Scholar 

  8. Tan W, Wu GY, Zheng CS. Imaging finding of primary hepatic leiomyoma. Chinese-German J Clin Oncol, 2009,8: 134–136.

    Article  Google Scholar 

  9. Wang Y, Shen Z, Zhu Z, et al. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat Mon, 2011, 11: 195–199.

    PubMed  CAS  Google Scholar 

  10. El-Serag HB, Kramer JR, Chen GJ, et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut, 2011, 60: 992–997.

    Article  PubMed  CAS  Google Scholar 

  11. Bertino G, Neri S, Bruno CM, et al. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med, 2011, 102: 363–371.

    PubMed  CAS  Google Scholar 

  12. Zhou L, Rui JA, Wang SB, et al. The significance of serum AFP cut-off values, 20 and 400 ng/mL in curatively resected patients with hepatocellular carcinoma and cirrhosis might be of difference. Hepatogastroenterology, 2012, 59: 840–843.

    PubMed  CAS  Google Scholar 

  13. Hu JS, Wu DW, Liang S, et al. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol, 2010, 27: 339–345.

    Article  PubMed  CAS  Google Scholar 

  14. Kladney RD, Cui X, Bulla GA, et al. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology, 2002, 35: 1431–1440.

    Article  PubMed  CAS  Google Scholar 

  15. Liu X, Wan X, Li Z, et al. Golgi protein 73 (GP73), a useful serum marker in liver diseases. Clin Chem Lab Med, 2011, 49: 1311–1316.

    PubMed  CAS  Google Scholar 

  16. Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol, 2005, 43: 1007–1012.

    Article  PubMed  CAS  Google Scholar 

  17. Hann HW, Wang M, Hafner J, et al. Analysis of GP73 in patients with HCC as a function of anti-cancer treatment. Cancer Biomark, 2010, 7: 269–273.

    PubMed  CAS  Google Scholar 

  18. Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol, 2010, 45: 1272–1282.

    Article  PubMed  CAS  Google Scholar 

  19. Gu Y, Chen W, Zhao Y, et al. Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem, 2009, 46: 38–43.

    Article  PubMed  CAS  Google Scholar 

  20. Ozkan H, Erdal H, Tutkak H, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion, 2011, 83: 83–88.

    Article  PubMed  Google Scholar 

  21. LU Y, Xia Y, Wang YH, et al. Expression of PADI4 in hepatocellular carcinoma. Chinese-German J Clin Oncol, 2009, 8: 453–455.

    Article  Google Scholar 

  22. Shams M, Al-Gayyar M, Barakat E, et al. Circulating adiponectin: a potential prognostic marker for hepatocellular carcinoma. Chinese-German J Clin Oncol, 2011, 10: 570–574

    Article  CAS  Google Scholar 

  23. Zhang G, Ha SA, Kim HK, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study. Dis Markers, 2012, 32: 265–271.

    PubMed  CAS  Google Scholar 

  24. Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open, 2012, 2: e000825.

    Article  PubMed  Google Scholar 

  25. Zhou Y, Yin X, Ying J, et al. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer, 2012, 12: 17.

    Article  PubMed  CAS  Google Scholar 

  26. Shi Y, Chen J, Li L, et al. A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat, 2011, 10: 287–294.

    PubMed  CAS  Google Scholar 

  27. Tian L, Wang Y, Xu D, et al. Serological AFP/golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer, 2011, 129: 1923–1931.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Laboratory, The Second People’s Hospital of Nanjing, Nanjing, 210002, China

    Zhenxian Zhou, Dunnian Xia, Wei Zhao & Chen Dong

  2. Medical Laboratory, Nanjing Red Cross Hospital, Nanjing, 210001, China

    Chaowei Wang

  3. Beijing Hotgen Biotech Co. Ltd., Beijing, 100070, China

    Changqing Lin

Authors
  1. Zhenxian Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dunnian Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chaowei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Changqing Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chen Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chen Dong.

Additional information

Supported by a grant from the International Collaboration Program from Nanjing Science and Technology Bureau (No. 201001139).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, Z., Xia, D., Wang, C. et al. Clinical evaluation of single or joint of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma diagnosing. Chin. -Ger. J. Clin. Oncol. 11, 650–654 (2012). https://doi.org/10.1007/s10330-012-1072-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-012-1072-z

Key words

Search

Navigation